Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Nov 11, 2021 11:19am
192 Views
Post# 34115032

RE:RE:RE:Crisper/ Onc partnership

RE:RE:RE:Crisper/ Onc partnership
analysts supposedly do not have access to different information than us but I think that they do have more access to talk to onc than the average shareholders which seem to be shut out for the most part. What I do find surprising is that onc did not give the partnership update that the analysts were asking for and yet held the rating although it has been pushed back...I do find it interesting that we even have any analysts following the stock as there is no institutions and they usually have analysts that follow the stock once invested so it is possible that we could loose their following eventually if nothing new were to happen fairly soon. I wish I knew what it would take to light a fire under this stock but definately has to be different than what has been presented otherwise we would have more buying and institutions interested but sadly no.So once again we look to the next quarter in hopes of something new to once again get us all excited and hopeful. It would be nice to have an institutional shareholder on the BOD as I find that this helps with oversight and not rubber stamping and more accountability. Oh well, same old story, looking forward to the next 12 months
<< Previous
Bullboard Posts
Next >>